Karsten Witt

Board member

Independent board member since 2011

Nationality: Danish

Age: 55

Dr Karsten Witt started at Array Biopharma, Inc in August 2011 as Vice President Clinical Science. In this role, he is responsible for the clinical strategy and execution of the development programs as well as the drug safety function.

Before this position, he was Sr Vice President Pharmaceutical Operations at OSI Pharmaceuticals, Inc in Melville, US, which he joined in 2002. Here he was intimately involved in the development of small-molecule targeted oncology therapies, including the EGFR inhibitor Tarceva® (erlotinib), which is being co-developed with Roche and Genentech.

Dr Witt has served as member of the Tarceva Tripartite Global Development Committee since 2007.

Prior to joining OSI Pharmaceuticals, Inc, Dr Witt served as Sr Director of Clinical Research & Drug Safety at NeXstar Pharmaceuticals and Gilead Sciences Inc.

He has been involved in succesful filing of six oncology INDs, three lung cancer filings, and one filing for pancreatic cancer - all leading to approval by the FDA and EMA - as well as two BLA/sBLA filings for hepatitis C, and one NDA for hepatitis B, resulting in regulatory approvals in the US and Europe.

Dr Witt furthermore has experience in clinical strategy and execution of development programs as well as drug safety/pharmacovigilance, development of small-molecule targeted oncology therapies, filing of INDs, BLA/sBLA, and NDA/sNDA.

Dr Witt is Doctor of Medicine from the University of Copenhagen and is presenter and author of numerous publications.